ReviewDrug and alcohol review2026
International Policy Approaches for Higher THC Cannabis Products: Are They Applicable to the Australian Medicinal Cannabis Framework?
Review in Drug and alcohol review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionThere have been concerted research efforts internationally to examine the health effects of higher delta-9-tetrahydrocannabinol (THC) concentration cannabis products and to design policies to reduce potential negative health effects of their use. This study identifies international policy approaches for regulating higher THC products relevant to the Australian medicinal cannabis program.
methodsAn environmental scan of international literature and policy as part of a broader study commissioned to inform Australian policy. Methods were prospectively registered with the Open Science Framework: 10.17605/OSF.IO/HNFUT. Peer-reviewed and grey literature on international policy approaches were identified through searches for 'high potency THC' and 'policy'. The literature was then narratively synthesised.
resultsWe identified 76 publications and other sources that described policy approaches recommended or implemented in five jurisdictions: Canada; Germany; the Netherlands; the United States; and Uruguay. Approaches included setting a threshold for cannabis flower THC concentration at or below the biological THC limit of 30%-35% found in the plant and a risk-tiered model for highly concentrated THC dosage forms. THC limits per dose and per package have been applied to edible products. Additional approaches included quantity limits, packaging and labelling requirements, pharmacovigilance, and education. DISCUSSION AND
conclusionsPolicy approaches for higher THC concentration cannabis products could be adapted to the Australian regulatory environment to reduce potentially harmful THC exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.